WYDUR Board Meeting Minutes
Members Present: Bill Harrison, Roxanne Homar, Deb Devereaux,
Kay Kohler, Becky Drnas, Dean Winsch, Kendra Grande, Aimee Lewis, Antoinette
Brown, Richard Johnson, Lenny Kosirog
Members Excused: Steve
Brown, George Zaharas, Mike Carpenter, Linda Martin
Guests: Dr. Melinkovich, Bobbie Cesko, Laura Miller, Patrick
Teegarden (Schering-Plough), Bert Jones (GSK), Alan Sloan (Purdue), Tim Hynek
(Lilly), Larry Bridger (Pfizer), Bob Schultz (BCBS-Wy), Jeff Jenkins (Merck),
Laura Hill (Takeda)
Dr. Kohler called the
meeting to order at
The minutes of the
Department of Health-
Prior Authorization
statistics: for PPIs $133.48 average per
claim cost prior to PA-currently $64.48 average per claim cost. For the period Jan-June 2004, savings are
$237,000.
For ACEI: prior to PA avg. per claim cost of $27.31 now
is $23.54 average per claim cost. Total
3 month savings = $23,525
Legislature: DAW legislation pending for this upcoming
session which would circumvent the PA/PDL process. The Board discussed narrow therapeutic index
drugs and what data there is to substantiate the NTI designation. The legislative special session has been meeting
to limit non-economic damages as part of tort reform. OB/GYN reimbursement codes were also bumped
up and help with malpractice insurance for OB/GYNs who deliver fewer than 35-50
babies per year.
The substance abuse
division has requested that the pharmacy program cover smoking cessation
products. The department will look at
potential usage. There may be some
general funds from the tobacco settlement to use for these products. There will be more information in September.
The APS group will
present their disease management programs to the DUR Board in September.
Prilosec OTC is in
short supply-the ACS help desk will allow the patients to have generic
omeprazole.
The State MAC program
will be expanding and a tiered co-pay will be implemented
The PDL Advisory Group
meeting for August was cancelled because the final reports from
The 2005-2006 budget
for the pharmacy program is $80.1 million.
About $5 million was removed from the requested budget amount. At the end of FFY 2004, $37.2 million (net of
rebates of $11.1 million) had been spent.
Average recipients per month have increased from 17,000 to 18,700. A supplemental budget request will be
submitted by August 2004.
Disease Management
programs-the Berlex MS program is at the IRB approval stage.
Neurontin-ACS now has
the ability to add ICD9 codes and provider specialty types. The Board discussed asking providers to enter
the diagnosis on the face of the prescription.
The Board discussed various strategies to deal with the off label usage
of Neurontin. The general perception is
that Neurontin is being used for pain as a drug of last resort--there are no
alternatives. Insuring provider access
has to be weighed against Neurontin restrictions which will be unpopular. The Board decided to ask APS to look at
Neurontin patients and providers, send out data on utilization and Dr.
Johnston's article to the top prescribers of Neurontin. Dr. Johnston will also provide a newsletter
article for the DUR newsletter. The
Board also requested that the PDL advisory committee consider Neurontin use for
pain during its review of the anticonvulsant category.
Dr. Johnston reviewed
the results of an analysis of asthma drug utilization. He will provide an article for the newsletter
on this analysis. A recommendation will
be sent to HID to add criteria for daily inhaled beta agonist use as high risk.
Kendra reported that
the Somatotropin review shows three patients that may need follow-up.
Alert changes: #132
suppress tricyclic antidepressants and SSRIs
Add criteria Spiriva and ipratropium is duplication
(Combivent and Atrovent)
There being no further
business the meeting was adjourned at
Respectfully Submitted,
Debra S. Devereaux MBA,
FASHP
DUR Manager